Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer

Hye Young Kim, Yunhee Cho, Hyeok Gu Kang, Ye Seal Yim, Seok Jun Kim, Jaewhan Song, Kyung Hee Chun

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is not yet studied in gastric cancers. In this study, we investigated the oncogenic role and therapeutic potency of targeting WEE1 in gastric cancer. At first, higher expression levels of WEE1 with lower survival probability were determined in stage 4 gastric cancer patients or male patients with accompanied lymph node metastasis. To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells. We also validated the clinical application of WEE1 targeting by a small molecule, AZD1775 (MK-1775), which is a WEE1 specific inhibitor undergoing clinical trials. AZD1775 significantly inhibited cell proliferation and induced apoptosis and cell cycle arrest in gastric cancer cells, which was more effective in WEE1 highexpressing gastric cancer cells. Moreover, we performed combination treatments with AZD1775 and anti-cancer agents, 5- fluorouracil or Paclitaxel in gastric cancer cells and in gastric cancer orthotopic-transplanted mice to maximize the therapeutic effect and safety of AZD1775. The combination treatments dramatically inhibited the proliferation of gastric cancer cells and tumor burdens in stomach orthotopictransplanted mice. Taken together, we propose that WEE1 is over-expressed and could enhance gastric cancer cell proliferation and metastasis. Therefore, we suggest that WEE1 is a potent target for gastric cancer therapy.

Original languageEnglish
Pages (from-to)49902-49916
Number of pages15
JournalOncotarget
Volume7
Issue number31
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Molecular Targeted Therapy
Stomach Neoplasms
Phosphotransferases
Cell Proliferation
Neoplasm Metastasis
Protein-Serine-Threonine Kinases
Therapeutic Uses
Therapeutics
Paclitaxel
Cell Cycle Checkpoints
Tumor Burden
Fluorouracil

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hye Young ; Cho, Yunhee ; Kang, Hyeok Gu ; Yim, Ye Seal ; Kim, Seok Jun ; Song, Jaewhan ; Chun, Kyung Hee. / Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. In: Oncotarget. 2016 ; Vol. 7, No. 31. pp. 49902-49916.
@article{994601ddadea4401ac63a83ed2df0d65,
title = "Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer",
abstract = "Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is not yet studied in gastric cancers. In this study, we investigated the oncogenic role and therapeutic potency of targeting WEE1 in gastric cancer. At first, higher expression levels of WEE1 with lower survival probability were determined in stage 4 gastric cancer patients or male patients with accompanied lymph node metastasis. To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells. We also validated the clinical application of WEE1 targeting by a small molecule, AZD1775 (MK-1775), which is a WEE1 specific inhibitor undergoing clinical trials. AZD1775 significantly inhibited cell proliferation and induced apoptosis and cell cycle arrest in gastric cancer cells, which was more effective in WEE1 highexpressing gastric cancer cells. Moreover, we performed combination treatments with AZD1775 and anti-cancer agents, 5- fluorouracil or Paclitaxel in gastric cancer cells and in gastric cancer orthotopic-transplanted mice to maximize the therapeutic effect and safety of AZD1775. The combination treatments dramatically inhibited the proliferation of gastric cancer cells and tumor burdens in stomach orthotopictransplanted mice. Taken together, we propose that WEE1 is over-expressed and could enhance gastric cancer cell proliferation and metastasis. Therefore, we suggest that WEE1 is a potent target for gastric cancer therapy.",
author = "Kim, {Hye Young} and Yunhee Cho and Kang, {Hyeok Gu} and Yim, {Ye Seal} and Kim, {Seok Jun} and Jaewhan Song and Chun, {Kyung Hee}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10231",
language = "English",
volume = "7",
pages = "49902--49916",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. / Kim, Hye Young; Cho, Yunhee; Kang, Hyeok Gu; Yim, Ye Seal; Kim, Seok Jun; Song, Jaewhan; Chun, Kyung Hee.

In: Oncotarget, Vol. 7, No. 31, 01.01.2016, p. 49902-49916.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer

AU - Kim, Hye Young

AU - Cho, Yunhee

AU - Kang, Hyeok Gu

AU - Yim, Ye Seal

AU - Kim, Seok Jun

AU - Song, Jaewhan

AU - Chun, Kyung Hee

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is not yet studied in gastric cancers. In this study, we investigated the oncogenic role and therapeutic potency of targeting WEE1 in gastric cancer. At first, higher expression levels of WEE1 with lower survival probability were determined in stage 4 gastric cancer patients or male patients with accompanied lymph node metastasis. To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells. We also validated the clinical application of WEE1 targeting by a small molecule, AZD1775 (MK-1775), which is a WEE1 specific inhibitor undergoing clinical trials. AZD1775 significantly inhibited cell proliferation and induced apoptosis and cell cycle arrest in gastric cancer cells, which was more effective in WEE1 highexpressing gastric cancer cells. Moreover, we performed combination treatments with AZD1775 and anti-cancer agents, 5- fluorouracil or Paclitaxel in gastric cancer cells and in gastric cancer orthotopic-transplanted mice to maximize the therapeutic effect and safety of AZD1775. The combination treatments dramatically inhibited the proliferation of gastric cancer cells and tumor burdens in stomach orthotopictransplanted mice. Taken together, we propose that WEE1 is over-expressed and could enhance gastric cancer cell proliferation and metastasis. Therefore, we suggest that WEE1 is a potent target for gastric cancer therapy.

AB - Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is not yet studied in gastric cancers. In this study, we investigated the oncogenic role and therapeutic potency of targeting WEE1 in gastric cancer. At first, higher expression levels of WEE1 with lower survival probability were determined in stage 4 gastric cancer patients or male patients with accompanied lymph node metastasis. To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells. We also validated the clinical application of WEE1 targeting by a small molecule, AZD1775 (MK-1775), which is a WEE1 specific inhibitor undergoing clinical trials. AZD1775 significantly inhibited cell proliferation and induced apoptosis and cell cycle arrest in gastric cancer cells, which was more effective in WEE1 highexpressing gastric cancer cells. Moreover, we performed combination treatments with AZD1775 and anti-cancer agents, 5- fluorouracil or Paclitaxel in gastric cancer cells and in gastric cancer orthotopic-transplanted mice to maximize the therapeutic effect and safety of AZD1775. The combination treatments dramatically inhibited the proliferation of gastric cancer cells and tumor burdens in stomach orthotopictransplanted mice. Taken together, we propose that WEE1 is over-expressed and could enhance gastric cancer cell proliferation and metastasis. Therefore, we suggest that WEE1 is a potent target for gastric cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84981301297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981301297&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10231

DO - 10.18632/oncotarget.10231

M3 - Article

C2 - 27363019

AN - SCOPUS:84981301297

VL - 7

SP - 49902

EP - 49916

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -